4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	77.16	149.34	249.11	52.35	153	276.73
Short-Term Investments	216.07	275.54	39.12	161.2	94.78	-
Cash & Short-Term Investments	293.23	424.88	288.23	213.55	247.78	276.73
Cash Growth	-45.89%	47.41%	34.97%	-13.81%	-10.46%	457.33%
Accounts Receivable	-	-	-	-	0.05	1.49
Other Receivables	-	-	-	-	0.7	-
Receivables	-	-	-	-	0.75	1.49
Prepaid Expenses	10.06	10.06	8.36	6.96	7.76	4.44
Total Current Assets	303.29	434.93	296.59	220.51	256.28	282.66
Property, Plant & Equipment	37.15	40.61	31.67	35.35	28.95	5.07
Long-Term Investments	123.81	80.58	10.95	4.91	67.65	-
Other Long-Term Assets	9.39	4.26	0.68	1.08	0.6	0.6
Total Assets	473.64	560.38	339.89	261.85	353.49	288.33
Accounts Payable	8.7	4.39	3.52	3.32	4.76	1.79
Accrued Expenses	19.19	18.87	12.01	8.87	7.74	8.37
Current Portion of Leases	5.72	5.64	3.15	2.66	1.23	-
Current Unearned Revenue	1.07	0.26	0.27	0.88	2.6	6.59
Total Current Liabilities	34.68	29.15	18.95	15.73	16.34	16.74
Long-Term Leases	17.36	18.97	11.52	13.47	15.22	-
Long-Term Unearned Revenue	0.22	1.06	0.97	1.08	2.49	13.23
Other Long-Term Liabilities	0.5	0.6	0.62	0.23	0.33	1.97
Total Liabilities	52.75	49.78	32.06	30.51	34.38	31.94
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-In Capital	1,099	1,087	723.14	547.02	526.52	392.06
Retained Earnings	-678.83	-576.2	-415.33	-314.49	-207	-135.68
Comprehensive Income & Other	0.34	0.23	0.02	-1.2	-0.42	-
Total Common Equity	420.89	510.61	307.83	231.34	319.11	256.39
Shareholders' Equity	420.89	510.61	307.83	231.34	319.11	256.39
Total Liabilities & Equity	473.64	560.38	339.89	261.85	353.49	288.33
Total Debt	23.08	24.61	14.67	16.12	16.45	-
Net Cash (Debt)	393.95	480.85	284.52	202.34	298.98	276.73
Net Cash Growth	-30.15%	69.01%	40.61%	-32.32%	8.04%	457.33%
Net Cash Per Share	7.07	8.91	7.27	6.25	10.78	43.03
Filing Date Shares Outstanding	46.7	46.3	49.78	33.23	32.24	26.69
Total Common Shares Outstanding	46.7	45.79	43.08	32.63	32.22	26.68
Working Capital	268.61	405.78	277.64	204.78	239.94	265.91
Book Value Per Share	9.01	11.15	7.15	7.09	9.90	9.61
Tangible Book Value	420.89	510.61	307.83	231.34	319.11	256.39
Tangible Book Value Per Share	9.01	11.15	7.15	7.09	9.90	9.61
Machinery	17.71	17.17	14.61	12.61	7.12	5.85
Construction In Progress	0.13	1.18	0.55	0.48	10.07	0.54
Leasehold Improvements	18.47	17.76	16.9	16.9	2.53	2.53

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q